Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5023-5031

  Chu, Qing ^a,b   Amano, Osamu ^a   Kanda, Yumiko ^a   Kunii, Shiro ^a   Wang, Qintao ^b   Sakagami, Hiroshi ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cell death; Cytotoxicity; Gefitinib; Hormesis; Oral squamous cell carcinoma

Indexed keywords

ANGELICA SINENSIS EXTRACT; ASCORBIC ACID; CASPASE 3; CISPLATIN; CORNUS OFFICINALIS EXTRACT; DOCETAXEL; DOXORUBICIN; DRYNARIA BARONII; FLUORIDE SODIUM; GEFITINIB; HERBACEOUS AGENT; METHOTREXATE; MITOXANTRONE; UNCLASSIFIED DRUG;

ANGELICA SINENSIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CELL DIVISION; CELL SURFACE; CELL ULTRASTRUCTURE; CYTOTOXICITY; DNA FRAGMENTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ASCORBIC ACID; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CISPLATIN; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; HL-60 CELLS; HUMANS; METHOTREXATE; MITOXANTRONE; MOUTH; MOUTH NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; QUINAZOLINES; SODIUM FLUORIDE; TUMOR CELLS, CULTURED;

EID: 75149188660     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M and Deisseroth AB: Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 89: 1271-1276, 1997.
2. Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, Miyata M, Oka H, Doki Y and Mori T: Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 71: 2902-2909, 1993.
3. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA and Wagener MM, Drenning SD and Tweardy DJ: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832, 1998.
4. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH: Biologiocal effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529, 1983.
5. Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N and Mendelsohn J: Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat 55: 267-283, 1999.
6. Wu X, Fan Z, Masui H, Rosen N and Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897-1905, 1995.
7. 1 arrest in prostatic cancer cell line DU145. Cancer Res 56: 3666-3669, 1996.
8. Ono M and Kuwano M: Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12: 7242-7251, 2006.
9. Herbst RS, Fukuoka M and Baselga J: Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956-965, 2004.
10. 1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol 40: 43-51, 2004.
11. Lee EJ, Whang JH, Jeon NK and Kim J: The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP-, uPAR-dependent mechanism. Ann NY Acad Sci 1095: 113-128, 2007.
12. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063, 2000.
13. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) J Clin Oncol 21: 2237-2246, 2003.
14. Shintani S, Mihara M, Nakahara Y, Aida T, Tachikawa T and Hamakawa H: Lymph node metastasis of oral cancer visualized in live tissue by green fluorescent protein expression. Oral Oncol 38: 664-669, 2002.
15. Shintani S, Li C, Mihara M, Nakashiro K and Hamakawa H: Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 201: 149-155, 2003.
16. Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K and Hamakawa H: Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107: 1030-1037, 2003.
17. Hambek M, Baghi M, Strebhardt K, Baumann H, Gstöttner W and Knecht R: Reduction of cisplatin dosage by ZD 1839. Anticancer Res 25: 3985-3988, 2005.
18. Mimeault M, Mehta PP, Hauke R, Henichart JP, Depreux P, Lin MF and Batra SK: Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades. Growth Factors 25: 400-416, 2007.
19. Choe MS, Chen Z, Klass CM, Zhang X and Shin DM: Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res 13: 3015-3023, 2007.
20. Chu Q, Satoh K, Kanamoto T, Terakubo S, Nakashima H, Wang QT and Sakagami H: Antitumor potential of three herbal extracts against human oral squamous cell lines. Anticancer Res 29: 3211-3219, 2009.
21. Satoh R, Kishino K, Morshed SRM, Takayama F, Otsuki S, Suzuki F, Hashimoto K, Kikuchi H, Nishikawa H, Yasui T and Sakagami H: Changes in fluoride sensitivity during in vitro senescence of human normal oral cells. Anticancer Res 25: 2085-2090, 2005.
22. Sekine T, Takahashi J, Nishishiro M, Arai A, Wakabayashi H, Kurihara T, Kobayashi M, Hashimoto K, Kikuchi H, Katayama T, Kanda Y, Kunii S, Motohashi N and Sakagami H: Tumor-specificity and type of cell deadi induced by trihaloacetylazulenes in human tumor cell lines. Anticancer Res 27: 133-144, 2007.
23. Yanagisawa-Shiota F, Sakagami H, Kuribayashi N, Iida M, Sakagami T and Takeda M: Endonuclease activity and induction of DNA fragmentation in human myelogenous leukemic cell lines. Anticancer Res 15: 259-266, 1995.
24. Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A and Ferlito A: Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 30: 800-809, 2008.
25. Chang GC, Yu CT, Tsai CH, Tsai JR, Chen JC, Wu CC, Wu WJ and Hsu SL: An epidermal growth factor inhibitor, gefitinib, induces apoptosis through a p53-dependent up-regulation of proapoptotic molecules and down-regulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur J Pharmacol 600: 37-44, 2008.
26. Pédeboscq S, L'Azou B, Passagne I, De Giorgi F, Ichas F, Pometan JP and Cambar J: Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. J Exp Ther Oncol 7: 99-111, 2008.
27. Lindhagen E, Eriksson A, Wickström M, Danielsson K, Grundmark B, Henriksson R, Nygren P, Aleskog A, Larsson R and Höglund M: Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 81: 344-353, 2008.
28. Sakagami H, Kawase M, Wakabayashi H and Kurihara T: Factors that affect the type of cell death induced by chemicals. Autophagy 3: 493-495, 2007.
29. Sebastian S, Azzariti A, Accardi R, Conti D, Pilato B, LaCalamita R, Porcelli L, Simone GM, Tommasi S, Tommasino M and Paradiso A: Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. Int J MoI Med 21: 809-817, 2008.